Matthew Vickers’ Post

Founders often get crushed by dilution when raising a Series A. Dilution is a product of capital raised and company valuation. Curie.Bio helps founders minimize dilution by maximizing progress with less capital. By reaching critical milestones on blockbuster TPPs, you can raise more capital at a much higher valuation. Last fall, our first portfolio company, Forward Therapeutics, Inc., raised a $50M Series A to generate clinic data. A recent Oppenheimer report revealed this raise was the BIGGEST valuation step up compared to all other therapeutics companies that raised a Series A in the last 12 months. The best part? The founders retained significant ownership in their company. That's the power of the Curie.Bio model. That's how we #freethefounders. If you have an exciting therapeutic idea, we'd love to collaborate. Contact our team or visit our website. https://lnkd.in/e4NWnqwF

🦾 Our Army Of 5,000 Shareholders Is Growing By The Day... Discover how our army of loyal Cytonics Corporation shareholders is propelling us towards revolutionizing regenerative medicine! 🖇 invest.cytonics.com 💸 Fundraising Triumphs: A Collective Achievement To date, we have raised over $25M in pursuit of developing the first and only therapy for osteoarthritis. This monumental effort boasts: ➡️ A $4M investment from Synthes (a medical device company acquired by Johnson and Johnson for $19B), alongside ➡️ $10M raised through equity crowdfunding, with ➡️ Over 100 orthopedic surgeons who utilize our APIC therapy for osteoarthritis and understand the significance of our drug development program. Our Cytonics family has expanded to over 5,000 shareholders who have played a pivotal role in our success through repeat investment, an outpouring of encouragement, and spreading the word. Every investor, regardless of the size of their committment, is a part of our family and treated as such. The current round has welcomed over 1,100 new shareholders, many of whom are placing their first equity crowdfunding investment (292 to be exact)! 🔍 A Closer Look Into Our Campaign The unwavering loyalty and commitment of our shareholders is a testament to the deep trust and shared goals that bind us. This round alone has raised over $2.7M from more than 1,100 investors, 60% of whom are returning shareholders. This remarkable rate of recurring investment is not just a metric of success but a beacon of the belief in our mission, confidence in management, and the impact of our research. ❤️ In Gratitude Your continued support and belief in Cytonics are more than just a financial decision; you are the driving force behind our relentless pursuit of improving human well-being. It's a shared journey towards creating long-term value and making a significant impact on the lives of those affected by osteoarthritis. #biotechnology #arthritis #investing #crowdfunding #venturecapital #healthcare #drugdevelopment #clinicaltrials #regenerativemedicine

#fundingalert 💼Company: Scorpion Therapeutics 💰Funding: $150 Million ⚡Round: Series C 👥Investors: Frazier Life Sciences , Lightspeed Venture Partners, Willett Advisors and leading #healthcare institutional investors, Omega Funds, Vida Ventures, Atlas Venture, Abingworth, Fidelity Management & Research Company, Boxer Capital, EcoR1 Capital, LLC, Surveyor Capital (a Citadel company), Invus, Wellington Management, Nextech Invest Ltd. (on behalf of one or more funds managed by it), OrbiMed, Logos Capital, Woodline Partners LP, and Casdin Capital, LLC. Scorpion is a pioneering clinical-stage oncology company redefining the frontier of precision medicine to deliver optimized and transformational therapies for larger populations of patients with cancer. Adam Friedman, MD, PhD Albert Cha Read more - https://lnkd.in/gHkJzyni To share your startup story write us on - contact@startuprise.io #Scorpion #fundraising #

🦾 Our Army Of 5,000 Shareholders Is Growing By The Day... Discover how our army of loyal Cytonics Corporation shareholders is propelling us towards revolutionizing regenerative medicine! 🖇 invest.cytonics.com 💸 Fundraising Triumphs: A Collective Achievement To date, we have raised over $25M in pursuit of developing the first and only therapy for osteoarthritis. This monumental effort boasts: ➡️ A $4M investment from Synthes (a medical device company acquired by Johnson and Johnson for $19B), alongside ➡️ $10M raised through equity crowdfunding, with ➡️ Over 100 orthopedic surgeons who utilize our APIC therapy for osteoarthritis and understand the significance of our drug development program. Our Cytonics family has expanded to over 5,000 shareholders who have played a pivotal role in our success through repeat investment, an outpouring of encouragement, and spreading the word. Every investor, regardless of the size of their committment, is a part of our family and treated as such. The current round has welcomed over 1,100 new shareholders, many of whom are placing their first equity crowdfunding investment (292 to be exact)! 🔍 A Closer Look Into Our Campaign The unwavering loyalty and commitment of our shareholders is a testament to the deep trust and shared goals that bind us. This round alone has raised over $2.7M from more than 1,100 investors, 60% of whom are returning shareholders. This remarkable rate of recurring investment is not just a metric of success but a beacon of the belief in our mission, confidence in management, and the impact of our research. ❤️ In Gratitude Your continued support and belief in Cytonics are more than just a financial decision; you are the driving force behind our relentless pursuit of improving human well-being. It's a shared journey towards creating long-term value and making a significant impact on the lives of those affected by osteoarthritis. #biotechnology #arthritis #investing #crowdfunding #venturecapital #healthcare #drugdevelopment #clinicaltrials #regenerativemedicine

Gene&Cell Therapy >> Forbion raises €2.1B for two new biotech funds after series of company exits: Dutch biotech investor Forbion has raised two new funds to put into biotech companies, just 18 months after its last major raise and following a series of successful exits in its portfolio. The new funds include a €1.2 billion ($1.3 billion) growth fund and a €890 million ($970 million) venture fund, Forbion announced Tuesday. Both funds are each expected to put the money to work across about 15 different companies. That includes startups working on cardiometabolic drugs, immunology and inflammation treatments, precision oncology and gene therapy, Forbion co-founder Sander Slootweg told Endpoints News in an interview. Slootweg said he’s keen to avoid some of the metabolic targets that have become crowded and potentially overpriced. “What everyone is going after will become expensive, and that’s what we’ve seen,” he said of the weight loss space. “We’ll go after new targets and new modalities, and there is still a lot of upside.” In gene therapy, Forbion will most likely look at in vivo approaches. It was an early investor in bluebird bio. Lyfgenia, the company’s ex vivo sickle cell disease gene therapy, is a scientific breakthrough but a commercial challenge. Sander Slootweg “Complexity equals cost,” Slootweg said. “If you can avoid ex vivo approaches, you should try to.” But he said the company had recently looked at such a treatment for a rare disease, and there are cases where manipulating cells outside the body might still be the only option. Forbion has been one of biotech’s most reliable fundraisers in an otherwise difficult capital environment. The two new funds come 18 months after the investor raised €1.35 billion for a growth fund and a venture fund. It’s been returning money to its investors through distributions as well. Its portfolio has had six exits in roughly the last year, largely through the sale of companies to large drugmakers. That includes Yellow Jersey Therapeutics, sold to Johnson & Johnson for $1.25 billion; a $1 billion upfront deal from Novartis for Mariana Oncology; and another $1 billion deal in which GSK acquired Aiolos Bio. In a volatile environment for biotechs, getting cash back to investors has made it much easier to raise new money, Slootweg said. “From an annual budgeting perspective, they expect an amount of distributions, and then there’s a limit to new allocations,” he said, talking about how fund investors are deploying capital to firms like his. Money back matters more than paper gains, Slootweg added: “People want to see distributed returns.” He took the recent run of biotech IPOs as a good sign for the industry, even though there have been none of the larger acquisitions by big pharma companies that marked the end of 2023 and the start of 2024. “We are… #lucidquest #genetherapy #celltherapy

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Athena Countouriotis' Avenzo nabs $150M to in-license more assets: Athena Countouriotis and her team at Avenzo Therapeutics have reeled in an additional $150 million just two and a half months after in-licensing their first clinical-stage asset. With the Series A-1, the biotech has now raised $347 million in total financing since its August 2022 inception, Avenzo told Endpoints News Tuesday morning. That makes it one of the largest Series A financings in recent biotech memory. Athena Countouriotis It also adds to a big financing month for the San Diego biotech scene. Autoimmune startup Mirador Therapeutics emerged with $400 million just last week and Countouriotis-chaired Capstan Therapeutics snagged $175 million for its in vivo CAR-T work. Meanwhile, two local startups disclosed their intentions to go public: Boundless Bio and Contineum Therapeutics. “This is a town that was, for the most part, third fiddle to San Francisco and Boston for so long, and I just love that there are multiple transactions and all those teams are coming back together,” Countouriotis said in an interview with Endpoints. Avenzo wasn’t expecting $150 million. The small biotech had targeted about one-third of that size, the CEO, president and co-founder said. “It’s nine investors that I’ve never worked with before, so it’s really a testament to not only the first asset that we have, but our team and also a peek at what we’re looking to bring in next, so we had quite a bit of demand,” Countouriotis said. Jakob Dupont The round was led by New Enterprise Associates, Deep Track Capital, Sofinnova Investments and Sands Capital. Sofinnova’s executive partner of private equity, Jakob Dupont, will join Avenzo’s board alongside the financing. “It’s not a down round but it’s also incredibly modest in regards to where we were on the Series A, really to set us up hopefully for success at an IPO,” the CEO said. A crossover round is on the road map for later this year or early next year, with an IPO to follow in 2025 or early 2026, she said. The ticker would be “AVZO” — a combination of the names of her two children. In August 2022, Countouriotis quickly formed the biotech after a successful $4.1 billion exit of Turning Point Therapeutics to Bristol Myers Squibb in June of that year. She had brought together a who’s who of investors: SR One, OrbiMed, Foresite Capital, Citadel’s Surveyor Capital and Lilly Asia Ventures. After a little over a year of searching, Avenzo’s pipeline kicked into gear in January when it paid Allorion Therapeutics $40 million upfront to get its hands on AVZO-021. The CDK2 inhibitor is being studied in patients with HR+/HER2- metastatic breast cancer and other advanced solid tumors in a Phase 1 in the US. With cancer patients developing resistance to… #lucidquest #genetherapy #celltherapy

🦾 Our Army Of 5,000 Shareholders Is Growing By The Day... Discover how our army of loyal shareholders is propelling us towards revolutionizing regenerative medicine! 🖇 invest.cytonics.com 💸 Fundraising Triumphs: A Collective Achievement To date, we have raised over $25M in pursuit of developing the first and only therapy for osteoarthritis. This monumental effort boasts: ➡️ A $4M investment from Synthes (a medical device company acquired by Johnson and Johnson for $19B), alongside ➡️ $10M raised through equity crowdfunding, with ➡️ Over 100 orthopedic surgeons who utilize our APIC therapy for osteoarthritis and understand the significance of our drug development program. Our Cytonics family has expanded to over 5,000 shareholders who have played a pivotal role in our success through repeat investment, an outpouring of encouragement, and spreading the word. Every investor, regardless of the size of their committment, is a part of our family and treated as such. The current round has welcomed over 1,100 new shareholders, many of whom are placing their first equity crowdfunding investment (292 to be exact)! 🔍 A Closer Look Into Our Campaign The unwavering loyalty and commitment of our shareholders is a testament to the deep trust and shared goals that bind us. This round alone has raised over $2.7M from more than 1,100 investors, 60% of whom are returning shareholders. This remarkable rate of recurring investment is not just a metric of success but a beacon of the belief in our mission, confidence in management, and the impact of our research. ❤️ In Gratitude Your continued support and belief in Cytonics are more than just a financial decision; you are the driving force behind our relentless pursuit of improving human well-being. It's a shared journey towards creating long-term value and making a significant impact on the lives of those affected by osteoarthritis. #biotechnology #arthritis #investing #crowdfunding #venturecapital #healthcare #drugdevelopment #clinicaltrials #regenerativemedicine

Spoke to Cody Shandraw earlier this week about the ongoing FDA priority review for Lykos Therapeutics MDMA-assisted therapy, and the chances of it passing. He firmly believes if approved by the FDA, with a slated time period of early August, that would we could see the following .. “I think you could see a market move unlike anything for an industry throughout public markets history” Does it seem bold? Well think about what’s happened this year. atai Life Sciences $50m investment into Beckley Psytech. Cybin Inc raising $150m with a number of strategic biotech investors. MindMed and the $175m they raised after their ground breaking phase 2 results. Reunion Neuroscience raising $103m. Not to mention, Lykos raised $100m back in January. If approved, you’re only going to see the valuation of this company increase dramatically. Check our latest podcast in the comment section. Doug Drysdale Robert Barrow Payton Nyquvest Cosmo Feilding Mellen Florian Brand Christian Angermayer Lars Christian Wilde E. Matthew ("Whiz") Buckley Elemer Piros Daniel Carcillo Joe Caltabiano Rob Crocker Graham Farrell Michael Boughner Tyler Beuerlein Michael Tan Rick Doblin Michael B. Galloro, CPA Barrington Miller #psychedelics #psychedelic #psychedelicstocks #mentalhealth #stocks

🔬 Major Milestone in Psychedelic Medicine: MAPS PBC, now Lykos Therapeutics, closes a landmark $100m Series A funding, signifying a significant step towards mainstreaming MDMA-assisted therapy in the United States of America. This rebranding and funding underscore a commitment to balancing public benefit with commercial viability, potentially revolutionising mental health treatment. Stay informed about this pivotal moment in psychedelic research and its impact on future therapies. #PsychedelicMedicine #MentalHealthInnovation Read More: https://buff.ly/3ROY8tN @PRISMNews supports psychedelic research. Help us by: Donating - https://buff.ly/3szdfJI Learning More - https://buff.ly/2UnaAER

Forbion is proud to announce our latest milestone in supporting groundbreaking advancements in the life sciences industry. We are thrilled to co-lead a $157 million Series B financing round in Engrail Therapeutics alongside F-Prime Capital Partners and Norwest Venture Partners . Engrail Therapeutics is at the forefront of developing transformative therapies for conditions such as anxiety disorders, depression, PTSD, and rare neurodegenerative diseases. Their lead asset, ENX-102, currently in phase II development for generalized anxiety disorder, holds immense promise in reshaping treatment paradigms and improving patient outcomes. The proceeds from this financing round will support Engrail's pipeline through critical stages of clinical development, bringing hope to millions of individuals grappling with these debilitating conditions. This achievement also underscores the strength of Forbion's Growth Opportunities II Fund, which raised €600 million in 2023. Engrail marks the ninth investment from this fund, reflecting our dedication to supporting European late-stage biopharma companies pioneering novel therapies in areas of profound medical need. Jasper Bos Melanie de Almeida Marc-Olivier Turgeon #LifeSciences #Biopharma #Innovation #Healthcare #Investment #EngrailTherapeutics